CD274 and neoplasm: It is designed to block immunosuppressive tumor signaling by targeting receptor or ligand checkpoint proteins, with typical targets including programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) (45).